Möchten Sie immer auf dem neuesten Stand bleiben?

Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model  Collaboration combines Regeneron’s leading antibody...

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly...

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading global network of electronic health record data Collaboration will expand...

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing...

TARRYTOWN, N.Y., March 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2026 financial and operating results on...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Srs. for Innovative Research

Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron’s global Phase 3 registrational program to be initiated later this year TARRYTOWN, N.Y., March 09, 2026 ...

TARRYTOWN, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation at the Barclays 28th Annual Global Healthcare Conference at...

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a...